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ABSTRACT
Splicing factor 1 (SF1) binds to the branch point
sequence (BPS) of mammalian introns and is
believed to be important for the splicing of some,
but not all, introns. To help identify BPSs, particu-
larly those that depend on SF1, we generated a BPS
profile model in which SF1 binding affinity data,
validated by branch point mapping, were iteratively
incorporated into computational models. We
searched a data set of 117 499 human introns for
best matches to the SF1 Affinity Model above a
threshold, and counted the number of matches at
each intronic position. After subtracting a back-
ground value, we found that 87.9% of remaining
high-scoring matches identified were located in a
region upstream of 30-splice sites where BPSs are
typically found. Since U2AF65 recognizes the
polypyrimidine tract (PPT) and forms a cooperative
RNA complex with SF1, we combined the SF1 model
with a PPT model computed from high affinity
binding sequences for U2AF65. The combined
model, together with binding site location
constraints, accurately identified introns bound by
SF1 that are candidates for SF1-dependent splicing.
INTRODUCTION
Most metazoan gene expression requires the splicing of
introns to generate mature mRNAs. Splicing is mediated
by the spliceosome, which consists of U1, U2, U4, U5 and
U6 small nuclear ribonucleoproteins (snRNPs) and more
than 150 non-snRNP proteins (1). Splicing proceeds
through two trans-esterification reactions: the first forms
a lariat intermediate with the 50-end of the intron linked to
an adenosine positioned within the branch point sequence
(BPS) and the second results in complete intron removal
and exon ligation (1).
Mammalian spliceosomes typically assemble on a
pre-mRNA substrate by forming an ATP-independent E
(early) complex, in which U1 snRNP binds the 50-splice
site and splicing factor 1 (SF1) and U2 auxiliary factor
(U2AF) bind cooperatively to elements near the 30-splice
site (1). SF1 recognizes the 7-nt BPS, the 65 kDa subunit
of U2AF (U2AF65) recognizes the polypyrimidine tract
(PPT), and the 35 kDa subunit of U2AF (U2AF35)
recognizes the AG dinucleotide adjacent to the 30-splice
site (2,3). U2AF65 is believed to then recruit U2 snRNP
to the pre-mRNA, where a conserved GUAGUA
hexanucleotide in U2 snRNA hybridizes to the BPS,
thereby releasing SF1 (4,5). The stable association of U2
snRNP with the 30-splice site (A complex) is the first
ATP-dependent step in the splicing pathway and specifies
the 20-OH of a bulged adenosine in the BPS as the
nucleophile for the first trans-esterification reaction (6,7).
However, trans-esterification only occurs after the forma-
tion of B complex through the joining of the U4/U5/U6
tri-snRNP to A complex and subsequent loss of U1 and
U4 snRNPs along with conformational rearrangements to
form the catalytically active B* complex (8).
The BPS in yeast introns is a nearly invariant
UACUAAC sequence with the branch point adenosine
(BP A) being the sixth nucleotide (highlighted). In
contrast, the BPS is highly variable in metazoan introns,
generally conforming to a YNCURAY consensus (BP A
highlighted, Y is a pyrimidine, N is any nucleotide and R
is a purine) (1). More recent work has demonstrated that
the human BPS may be even more degenerate and repre-
sented by a 5-mer sequence, YUNAY, rather than a 7-mer
(9). Consequently, it has been difficult to identify
metazoan BPSs based on sequence alone. BPSs are fre-
quently located 15–45 nt upstream of the 30-splice site,
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but have also been found much further upstream, further
complicating their identification (1,10,11). Introns with
multiple BPSs also exist and may be spliced by unusual
mechanisms, such as the recursive mechanism used to
completely remove a single intron in Drosophila (11,12).
BPS variations between isoforms of a single gene can
affect splice site choice and result in variable exon inclu-
sion, as observed in the third intron of the HLA-DQB1
gene (13,14). Such variations may provide an important
source of transcript diversity. Furthermore, BPS muta-
tions have been linked to several human genetic diseases
(15–19), providing further incentive to understand how
BPS variation contributes to splicing decisions.
SF1 binds the BPS using its KH domain (20,21) and
forms a cooperative complex with U2AF (2), but its role
in splicing has not been proven unambiguously.
Conditional mutants of the Saccharomyces cerevisiae
SF1 ortholog show reduced splicing of reporter genes
containing weak splice sites but not strong splice sites,
suggesting that SF1 may participate in the splicing of
some, but not all, introns (22). Immunodepletion of SF1
from HeLa cell nuclear extracts does not generally block
splicing but can affect the rate of spliceosome formation,
dependent on the nature of the BPS. For example, a
human IgM pre-mRNA engineered with the yeast consen-
sus BPS recruits U2 snRNP three times faster than with its
native BPS (23). RNAi-mediated SF1 depletion in HeLa
cells showed little effect on splicing, as assayed by
RT–PCR of a limited set of introns (24), but the activity
of any SF1 remaining after such depletion is difficult to
evaluate. Thus, SF1 can bind the BPS directly and the
available evidence suggests that it may be required for
the splicing of some introns, particularly those with
weak splice sites, but no specific SF1-dependent introns
have yet been identified.
Efforts to computationally identify BPSs in genomic
sequence data have proven challenging given the short,
degenerate nature of the BPS sequence motif, the limited
number of experimentally defined BPSs, and the variable
location of BPSs within introns, which limits the useful-
ness of sequence alignment tools. An analysis of BPS se-
quences in orthologous human and mouse introns
revealed conservation of BPS location and identical
sequences in only 32% of alternatively spliced and 3%
of constitutively spliced exons (25). Previous methods
relying on sequence-based models have met with some
success (1,13,25,26), but a comparative model analysis
has not been performed and BPS predictions have not
been experimentally verified, making it difficult to gauge
the relationship between statistical and biological success
of the models. Here we report a complementary approach
using SF1 RNA-binding affinity data to generate a BPS
profile model, which is then iteratively refined using
additional binding and branch point mapping data. We
have combined this model with a PPT profile model based
on sequences with high affinity for U2AF65, along with
the distance between BPS and PPT binding sequences to
approximate the cooperative interaction of SF1 and
U2AF65, to examine a data set of nearly 120 000 human
introns. The model can discriminate introns that bind SF1
from those that do not in high- and low-scoring cases,
thereby identifying human intron candidates for
SF1-dependent splicing.
MATERIALS AND METHODS
Intronic region data set
We utilized full-length mRNA sequences from a Homo
sapiens RefSeq data set (NCBI, build 35.1) (27), using
Spidey version 1.40 (28) to align mRNAs to the genome
and determine intron positions. Intronic regions were
defined as nucleotides 199 to +1 relative to the
30-splice site, or extended upstream of the intron for
shorter (<199 nt) introns. We eliminated redundancy in
which 30-splice sites were used in multiple mRNA
isoforms, resulting in 117 499 sequences. Seven 30-splice
sites had a second upstream 30-splice site within 200 nt,
and 13 628 introns were short and had exons located
within 200 nt. After constructing profile models, the data
set was annotated with the sequence, location, and scores
of the three highest scoring matches for the SF1 Affinity
Model, and the highest scoring matches for the Literature
BPS Model and U2AF65 Affinity Model in the
expected PPT region (from 30 to 11). The data set
also includes the distances between the BP A and
U2AF65 Affinity Model site, the RefSeq mRNA and
contig sequence identifiers and positions, the intron
and the downstream exon lengths, and the type of
splicing event (50/30, alternative/constitutive, first/last/
middle exon, insertion/retention). These data are available
upon request.
Construction of profile models
Sequence logos were generated from sequence alignments
using Weblogo (29,30) and log-odds scoring matrices were
generated using motifBS (31). Log-odds scores were
represented in bits for each profile model. For all models
except the SF1 Affinity Model described below, a uniform
background frequency of 0.25 for all bases was assumed
and a pseudocount of 1 was added for each nucleotide.
The Initial SF1 Binding Model was based on nine
sequences previously known to bind SF1 (UACUAAC,
UACUGAC, UAGUAAC, UAGUGAC, UACUAAU,
CACUAAC, GACUAAC, UACUAAG, UGCUAAC,
CACUGAC) (3,14), each represented once in a multiple
sequence alignment (‘uniform weighting’). To incorporate
SF1 binding data, each of 46 experimentally tested
sequences (Figure 3) was represented multiple times in pro-
portion to its affinity (‘affinity weighting’) (Supplementary
Table S4), with UACUAAC, the tightest binding previ-
ously known SF1 site, present at 100 copies. Because
adding multiple sequence copies did not add more infor-
mation, we used pseudocount scaling to keep a constant
ratio of 0.087 pseudocounts per sequence. During model
refinement, we used an Interim SF1 Affinity Model to aid
in selecting candidate BPSs and PPTs for branch point
mapping experiments, using affinity data for 23 of the
46 sequences that eventually were used to construct the
final SF1 Affinity Model.
In addition to the two SF1-based models, we generated:
a ‘YNCURAY Model’ to represent base frequencies
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of the mammalian BPS consensus (1), using uniform
weighting of all sequences conforming to the
YNCURAY consensus sequence; a ‘Pentamer BPS
Model’ to represent a previous model based on the
30-pentamer portion of BPSs from several species (26) by
extracting nucleotide frequencies from the publication and
converting them to log-odds scores; and a ‘Literature BPS
Model’ using uniform weighting of 14 initially defined
BPSs (32) and 13 additional experimentally validated
sites (15–19,33–36). In addition, we created a ‘U2AF65
Affinity Model’ to represent the PPT using uniform
weighting of sequences from a manually edited multiple
alignment of in vitro selected high affinity U2AF65
binding sequences (37). The sequence logo from this
U2AF65 alignment suggested a dimeric motif, where
each monomer had similar information content
(Supplementary Figure S1). Therefore only the 30-half of
this putative motif, corresponding to positions from 13 to
23 of the alignment, was used to construct the U2AF65
Affinity Model. We considered the first nucleotide from
the 50-end of the PPT to be the location at which the
model matched the intron.
Evaluation of profile models
To evaluate each model, we first established bit score
thresholds by generating all possible sequences of the
same length as the profile model, scoring each (in bits),
and setting a threshold corresponding to the top 1=Leff of
all scores (0.5%), where Leff is the number of possible
sites in a sequence (194 for a 200-nt sequence and 7-mer
motif) and thus the number of independent trials needed
for a Bonferroni correction. To identify best matches
within the introns, we corrected for tied scores by
weighting each as 1/n, where n is the total number of
matches for a given score in a given intron. The number
of ‘best matches’ at a position is the sum of weightings of
each of the best matches above the threshold at a particu-
lar position.
To estimate background values (Mbg), we averaged the
number of profile matches for the first 100 nt of each
intron region (from 189 to 90), all above the score
thresholds. Mean backgrounds in the expected regions
were defined as Mbg  Lexp, where Lexp is the length of
the expected region (30 nt from 45 to 16 for the BPS,
and 20 nt from 30 to 11 for the PPT). The fraction
of best matches in the expected BPS region at each
position was therefore calculated by dividing the number
of best matches in the peak region after subtracting
background matches, by the total number of best
matches anywhere in the intron after subtracting
background matches.
Signal-to-noise ratios (SNRs) were calculated for the
BPS and PPT profile models in their respective expected
regions. Noise was defined as the expected number of
mean background matches in the expected regions
ðMbg  LexpÞ and signal as the total number of matches
in the expected region minus those expected to be noise,
with SNR calculated using
Aexp  Mbg  Lexp
 
Mbg  Lexp ,
where Aexp is the number of ‘best matches’ in the expected
region. The SNR and information content are not neces-
sarily expected to have a direct relationship because the
values used for background subtraction and significance
threshold differ between models and thus are not directly
comparable.
In vitro branch point mapping
Candidate BPS and PPT pairs for branch point mapping
were selected from 1667 introns in 242 genes highly
expressed in HeLa cells, identified using microarray data
from the NCBI Gene Expression Omnibus (data set
accession GDS885; http://www.ncbi.nlm.nih
.gov/geo/gds/gds_browse.cgi?gds=885) (38). Four
replicate microarray data sets were used (GEO sample
accessions: GSM23372, GSM23373, GSM23377,
GSM23377) from an experiment using the Affymetrix
GeneChip Human Genome U133 Array (HG-U133A)
platform (39). Candidates for the assay included only
genes present in all data sets, having mean signal
intensities >1 Z-score (relative to the mean signal intensity
of all gene features in all replicates), and with standard
deviations of signal intensities <1 Z-score (relative to
the standard deviation of signal intensity of all gene
features in all replicates). From the resulting set of
genes, seven introns were chosen using the following
criteria: high (>10 bits) or medium (4–8 bits) PPT
scores; high (>7 bits) BPS scores using an interim SF1
affinity-weighted profile model; 35 nt spacing between
the BP A and the start of the PPT; and intron location
near the 30-end of the mRNA to facilitate in vitro reverse
transcription.
The BPS and PPT of a single intron in a Drosophila
melanogaster Ftz pre-mRNA was replaced with BPSs
and PPTs of the seven chosen introns by cloning PCR
products into a Ftz-expressing vector (40). Variant
plasmids were linearized with XhoI and runoff transcrip-
tion was performed to generate uniformly 32P-labeled
pre-mRNAs (41). The variant pre-mRNAs were gel
purified and incubated in HeLa nuclear extracts for
45min under previously described splicing conditions
(42). Splicing products were resolved on a denaturing
12% polyacrylamide gel and RNAs corresponding to
lariat/30-exon intermediates were purified. A portion of
the RNA was enzymatically debranched (43) and
analyzed on a 6% denaturing polyacrylamide gel to
confirm the identity of the lariat/30-exon intermediate.
To map branch sites by primer extension, 50 pmol of a
synthetic oligonucleotide primer complementary to the
30-exon of Ftz (50-AGCGGGTGTACGTCTGAC
GGG-30) was 50-end-labeled, aliquots (1 106 counts)
were annealed to either branched or debranched lariat/
30-exon RNAs, and RNAs were reverse transcribed
using Superscript II (Stratagene) as previously described
(36). After removing RNA by alkaline hydrolysis, primer
extension products were analyzed on a denaturing 6%
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polyacrylamide gel, using Ftz plasmid DNA sequenced
with the same primer as markers.
Predicted SF1–BPS interactions tested using the
Tat-hybrid assay
To determine whether the SF1 Affinity Model could be
used to identify SF1-binding introns, we chose 25 introns
with high- and low-scoring BPSs for testing in the
Tat-hybrid assay. The following criteria defined an
initial set of candidate introns: a predicted BP A based
on the 50-most best match to the SF1 Affinity Model
which was 50 nt upstream of the 30-splice site and
10 nt upstream of the start of the PPT as inferred from
the U2AF65 Affinity Model, and a PPT defined as the top
scoring 50-most match to the U2AF65 Affinity Model with
a starting position in the region from 30 to 11, with
high or low PPT scores. To describe the scores of the
selected intronic regions relative to distributions of
profile model scores, we calculated profile model
Z-scores based on the mean and standard deviation of
the distribution of bit scores for all possible 7-mers for
the SF1 model and all 11-mers for the PPT model. For
the SF1 model, we also computed percentiles based on the
distribution of scores of all above-threshold matches, or
all best matches if the score was below threshold, in the
expected BPS region in the set of 117 499 introns.
Ten introns with high BPS scores (7.1 bits, average
Z-score=3.6, and 12th percentile) were chosen from the
high-scoring PPT set (11.7 bits, average Z-score=4.4),
10 with the lowest BPS scores (2.4 bits, average
Z-score=1.9, and bottom first percentile) were chosen
from the high-scoring PPT set (10.0 bits, average
Z-score=3.9), and five with low-BPS scores (1.9 bits,
average Z-score=1.8, and bottom first percentile of all
matches) were chosen from the low scoring PPT set (1.0
bits, average Z-score=1.8). For the high BPS/high PPT
set, we chose predicted BPSs that also matched sequences
used to construct the Literature BPS Model to increase the
likelihood that the site would be a functional BPS in
addition to binding SF1.
For each of the 25 introns chosen, HIV-1 LTR reporters
containing 100 nt immediately upstream of the 30-splice
sites were constructed in an IRES firefly luciferase (FFL)
plasmid (3). The inserted sequence of the BPS reporter,
beginning at the 50-end of the transcript and encompassing
the BPS, AdML PPT and AG dinucleotide (shown in
boldface, with ‘X’ representing any nucleotide within the
BPS) is 50-GGTCTCTCTGGCTTAAGTTCGXXXXXXX
CCTGTCCCTTTTTTTTCCACAGCAAGCTT-30, with
the AflII and HindIII sites underlined (3). Plasmids
expressing Tat (residues 1–72) fused to SF1 (residues
2–307) or U2AF65 (residues 2–475) with a linker of
three glycines were described previously (3). For
Tat-hybrid assays, 25 ng of a BPS FFL reporter plasmid
typically was cotransfected with 25 ng of an HIV-1 TAR
Renilla luciferase (RL) reporter and 5 ng of a Tat-fusion
expressor plasmid into HeLa cells using Polyfect (Qiagen)
or Lipofectamine 2000 (Invitrogen). FFL and RL
activities from triplicate transfections were measured
after 48 h using Dual-Glo luciferase assays (Promega).
FFL values were normalized to RL values, which inde-
pendently monitor Tat-fusion expression levels by activa-
tion of the HIV-1 TAR reporter by the Tat portion of the
fusion, and to FFL values from parallel transfections
without the expressor to determine fold activation levels
over basal transcription. Data are presented as percent of
UACUAAC activity or fold activation over reporter
alone.
RESULTS
An initial BPS profile model based on SF1 binding
sequences
The sequence requirements for the BPS overlap with the
SF1 binding site to an unknown but significant degree, as
suggested by the high affinity of yeast and mammalian
SF1 for the UACUAAC yeast BPS (20). We reasoned
that this overlap might be exploited to help identify
BPSs, particularly those that utilize SF1 for splicing, and
constructed a BPS profile model using sequences bound by
SF1 with varying affinities. An initial model (initial SF1
binding model) was constructed using nine equally-
weighted experimentally-determined SF1 binding se-
quences, five of which also are experimentally validated
BPSs (see ‘Materials and Methods’ section for sequences)
(3,14). Nucleotide frequencies were incorporated into a
log-odds scoring matrix, which was used to predict BPSs
in a set of 117 499 unique human intronic regions, each
consisting of 199 nt upstream of the 30-splice site and the
first exonic nucleotide. To enrich for high-scoring
matches, we applied a bit score threshold such that no
more than one random match would be expected per
intronic region. The top-scoring matches, corresponding
to putative BPSs scoring above threshold, are distributed
across the intronic region (Figure 1). A peak is observed
from positions 45 to 16, corresponding to a region of
frequently observed BPSs (1,10,11) and referred to as the
expected BPS region, with a similar distribution to that
previously observed (44). A plateau of matches is observed
for all analyzed positions between 50 and 199. A peak
is also observed at the 4 position that may reflect
overlapping sequence preferences between the BP adeno-
sine and the PPT (Figure 1 legend). Two other models
(SF1 Affinity Model and Literature BPS Model) described
below, as well as the mammalian YNCURAY consensus,
show similar distributions (Figure 1). The distribution of
matches to a U2AF65 Affinity Model, generated using
sequences that are tightly bound by U2AF65 (37), shows
the expected location of PPTs directly upstream of
30-splice sites.
Of the 117 499 human introns, 65 813 introns (56%)
were found to have at least one best profile match with
a score above threshold, using the Initial SF1 Binding
Model (‘Materials and Methods’ section). We considered
only the best match of the model to the intron, accounting
for tied scores proportionately at each matched position,
leading to a fractional measure of best matches at each site
of a predicted BP A. We next calculated an average back-
ground level of best matches at each position in the range
from 189 to 90 from the 30-splice site. After subtracting
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this background value from the actual number of best
matches, 88.4% of remaining best matches above thresh-
old identified by the Initial SF1 Binding Model were
located in the expected BPS region, from 45 to 16.
To evaluate profile model performance, we calculated
the SNR ratio. The signal value was defined as the
number of best matches above threshold in the expected
BPS or PPT region minus the background estimate, while
the noise was defined as the estimate of background
matches (‘Materials and Methods’ section). The resulting
SNR value of 0.81 suggests low enrichment for BPSs but
may be an underestimate, in part because the estimate of
background matches includes functional BPSs that occur
upstream of the expected BPS region.
Branch point mapping validates BPS predictions
Given the low SNR of the Initial SF1 Binding Model, we
performed in vitro branch point mapping (36,43) to help
evaluate profile model predictions. We selected seven
introns, all from genes highly expressed in HeLa cells,
with high-scoring BPSs, intermediate- to high-scoring
PPTs, and spacings between the BP A and the start of
the PPT consistent with a cooperative SF1-U2AF65 inter-
action (‘Materials and Methods’ section; Supplementary
Table S1). We engineered these BPS and PPT regions into
a D. melanogaster fushi tarazu (Ftz) pre-mRNA, known to
splice robustly in HeLa cell nuclear extracts (40),
performed in vitro splicing reactions, and mapped the
branch points from purified lariat and 30-exon intermedi-
ates using primer extension (Figure 2). Six of the seven
introns tested showed the BP A at the predicted
position. The one exception (AP2M1 intron 11) mapped
to an adenosine 1 nt upstream of the predicted BP
A (UUCUAAC versus UUCUAAC). This result is con-
sistent with the observations that U2 snRNA can
hybridize to adenosines at either positions 5 or 6 of the
BPS, bulging out the other (45), and that reverse tran-
scriptase can stop within 1 nt of the branch point
(46,47). Thus, it appears that all of the selected BPSs are
indeed functional.
Initial SF1 binding model predicts SF1 binding sites
We next wished to assess whether the Initial SF1 Binding
Model could correctly identify SF1 binding sites. We
selected a range of BPS scores, including 10 of the
highest scoring sequences and 8 of the lowest scoring
sequences (including 3 sequences tied for the lowest
score). We also examined all of the sequences that were
identified as best matching the model in the expected BPS
region of each intron, and from these selected the 11
sequences found most frequently. Finally, we examined
all of the sequences identified by the model in the
expected BPS region of each intron and selected two fre-
quently observed sequences (Supplementary Table S2).
We engineered the sequences into the Tat-hybrid system,
in which transcription is activated at the HIV promoter
using a fusion between an RNA-binding protein and the
HIV transcription activator, Tat (Figure 3A). In this case,
a fragment of SF1 (residues 2–307) was fused to the
C-terminus of Tat (residues 1–72). This fusion protein
can be recruited to a HIV-1 promoter engineered with a
BPS, adenovirus major late (AdML) PPT, and 30-splice
site AG dinucleotide, which replace the cognate HIV Tat
trans-activating RNA (TAR), and thereby activate
transcription of a FFL reporter (Figure 3A) (3). This
cellular reporter system supports assembly of multi-
protein complexes with endogenous proteins, including
U2AF65, and has been used to demonstrate a requirement
for cooperative interaction between SF1 and U2AF65 in
binding to the BPS and PPT (3).
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Figure 1. Comparison of SF1 binding models to other profile models. Results of profile model searches in 117 499 human intronic regions (nu-
cleotides from 199 to +1 relative to the 30-splice site). For BPS models, the number of best matches above threshold (‘Materials and Methods’
section) was plotted based on the location of the predicted BP A. For the U2AF65 Affinity Model the number of best matches above threshold was
plotted using the 50-start position of the predicted PPT. The dotted box represents the expected BPS region (from 45 to 16). The area under the
curve in the expected region, in excess of the number of background matches estimated from the number of matches at positions from 198 to 90,
was used to evaluate and compare the models (‘Materials and Methods’ section). An unexpected sharp peak at position 4 was observed in all BPS
models. This is the single position where the BP A does not conflict with the preferred pyrimidine preferences of the PPT. Indeed, a BP A has been
mapped to position 4 of intron 3 of the human XPC gene, which also has a second BP A at position 24. Mutation of either BPS results in a
variably penetrant form of familial xeroderma pigmentosum (18). The BPS with a BP A at position 24 is the top-scoring match for the SF1 Affinity
Model while the BPS with BP A at position 4 also scores above threshold. The inset shows the distribution of profile matches with the y-axis scaled
to display the complete profile match distribution for the U2AF65 Affinity Model.
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Of the 10 highest scoring sequences, 7 were at least 50%
as active as the UACUAAC reporter, the best SF1 binder
reported to date (Figure 3B) (3,20), whereas only 2 of the 8
lowest scoring sequences (AUAACCA and GUCUUGA)
gave a minimum of 50% activity, and most are very poor
binders (Figure 3C). Interestingly, AUAACCA does not
conform to the YNCURAY mammalian consensus and
lacks adenosine at the branch position, but is bound by
SF1 comparably to UACUAAC. It is possible that
AUAACCA may be an unusual BPS or may bind SF1
but does not function as a BPS. Alternatively, if the site
were shifted by 1 nt to the adjacent UAACCAC sequence,
the score would improve substantially (from 7.97 to
3.81). Similarly, shifting GUCUUGA by 1 nt to the
adjacent UCUUGAC would increase the score from
3.11 to 2.74, shifting ACAGUCA to CAGUCAC
would increase the score from 8.37 to 2.06, and
shifting ACUACCA to CUACCAC would increase the
score from 8.70 to 3.84. In contrast, several sequences
that had low bit-scores and bound SF1 poorly did not
have alternate registers with higher scores, such as
CGAACAG (4.34), ACGGUGG (11.24), UGAGUAG
(3.30), ACGGCGG (10.61) and UAGUGAC (5.15).
However it is difficult to systematically account for
possible register shifts because we cannot directly ascer-
tain whether the measured activity results from a shifted
binding site. Of the 11 frequently observed sequences
tested, SF1 binds seven with at least 50% the activity of
the UACUAAC reporter (Figure 3D). As a control, no
SF1 binding was observed with reporters containing a
mutant PPT (data not shown), which eliminates
U2AF65 binding and the cooperative interaction with
SF1 (3). Thus, BPS scores calculated using the Initial
SF1 Binding Model discriminate between binding and
non-binding sequences.
We found four genes reported to have BPS mutations
associated with genetic disease: tyrosine hydroxylase (TH)
intron 11, lecithin cholesterol acetyltransferase (LCAT)
intron 4, integrin beta 4 (ITGB4) intron 31, and collagen
5A1 (COL5A1) intron 32 (15–17,19). Each of the mutant
BPSs had a lower score by the Initial SF1 Binding Model
than its corresponding wild-type BPS. In the reporter
assay, all wild-type sequences showed moderate to weak
SF1 binding and three of the four showed a
non-significant reduction in binding upon mutation, with
the LCAT BPS mutant having the most significant
decrease when the conserved U at position 4 was
changed to C (Figure 3E). In contrast, the same U
changed to G in the COL5A1 BPS resulted in an unex-
pected increase in SF1 binding. The relatively weak
activities observed do not obviously support a role for
SF1 in binding to these BPSs, but we note that the sites
in these reporters were placed in the context of the strong
adenovirus PPT and not in their natural intronic contexts.
To expand our data set of SF1 binding sequences and to
allow us to further evaluate and refine the computational
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Figure 2. Branch point mapping of initial model predictions. Seven introns were chosen for branch point mapping in the genes indicated (HUGO
gene identifiers), with the predicted BPSs shown and the predicted BP A’s highlighted. Ftz WT corresponds to the D. melanogaster fushi tarazu
pre-mRNA containing its native BPS and PPT while all others represent the Ftz pre-mRNA engineered with predicted BPSs and PPTs from:
ZMPSTE24—zinc metalloproteinase STE24 intron 8; CDC20—cell division cycle 20 intron 8; HMGN3—high-mobility group nucleosomal binding
domain 3 intron 5; PPS1—phosphoribosyl pyrophosphate synthase intron 6; snRNP F—small nuclear ribonucleoprotein F intron 2; MSN—moesin
intron 11; AP2M1—adaptor-related protein complex 2, mu 1 intron 11. For each intron, DNA sequencing lanes were used to locate the branch
point, observed as reverse transcriptase stops in primer extensions reactions. The ‘dbr’ lanes are primer extensions performed on purified lariat/30-
exon intermediates treated (+) or not treated () with debranching enzyme. Red dots correspond to predicted branch points and arrows correspond
to mapped branch points. Of note, the mapped branch point for HMGN3 intron 5 is interpreted as the same as the predicted branch point. However,
the darkest band on the gel corresponds to the location of the cytosine at position 7. This is in keeping with the observation that reverse transcriptase
can stop within a nucleotide of the actual branch point, as described in the text.
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Figure 3. SF1 binding to BPS reporters using the SF1 affinity Tat-hybrid assay. (A) Tat-hybrid system showing the HIV-1 FFL reporter engineered
with the BPS, PPT and AG dinucleotide. In the absence of Tat-fused SF1, transcription elongation is arrested. Recruitment of the Tat fusion through
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Tat-hybrid assays for BPSs predicted by the Initial SF1 Binding Model; (B) 10 of the high-scoring sequences; (C) 8 very low-scoring sequences;
(D) 11 sequences with high frequency rankings relative to all profile matches in the expected BPS region above a score threshold (‘Materials and
Methods’ section); (E) wild-type and mutant BPS variants found in genetic diseases: TH—tyrosine hydroxylase intron 11; LCAT—lecithin cholesterol
acetyltransferase intron 4; ITGB4—integrin beta-4 intron 31; COL5A1—collagen 5A1 intron 32; (F) the 10 remaining UACUAAC point mutants not
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model, we determined the activities of UACUAAC point
mutants at each of the seven positions. Of the 21 possible
single nucleotide substitutions, 11 were already present in
the set of high frequency and high-scoring sequences. Of
the 10 remaining unique sequences, six were substituted in
the conserved U at position 4 or the conserved A at
position 6, suggesting that these would be bound poorly
(21) and indeed, we observed that only 1 of these 10 se-
quences (AACUAAC) bound SF1 above the 50%
UACUAAC value (Figure 3F). While these single point
mutations can significantly reduce SF1 binding, their bit
scores generally are close to those of the high-scoring se-
quences (Supplementary Table S2). Thus, while the Initial
SF1 Binding Model discriminates reasonably well between
tight- and weak-binding sequences, it performs relatively
poorly for intermediate affinities. The Pearson correlation
coefficient between bit scores and SF1 affinities for the
highest and lowest scoring sequences (‘Materials and
Methods’ section) is 0.47, but it is only 0.29 for the
entire set of 46 sequences assayed (Figure 3G). The lack
of a strong correlation is consistent with under-sampling
of the 16 384 possible 7-mers, but the model performed
particularly poorly when considering sequences with inter-
mediate SF1 affinities and required further refinement.
An SF1 affinity-weighted BPS profile model and model
comparisons
The branch point mapping and SF1 binding data
encouraged us to test whether the model could be
refined by explicitly incorporating affinity data. We
chose to use data from the Tat-hybrid assays rather than
in vitro binding data, as Tat-hybrid assays more likely
represent in vivo assembly and cooperative U2AF
complexes. We generated an SF1 Affinity Model in
which the 46 sequences tested for binding were propor-
tionally weighted according to their measured affinities
(‘Materials and Methods’ section). This model produced
a similar location distribution of profile matches as the
other models (Figure 1). Of the set of 117 499 human
intron sequences, 65 018 (55%) had profile matches with
scores above threshold. After subtracting the average
background from each position as before, 87.9% (9868)
of remaining best matches were located in the expected
BPS region (‘Materials and Methods’ section) (Figure 4).
We compared our SF1 affinity-based models to three
others: the mammalian YNCURAY consensus, a previ-
ously published pentamer model (26), and a ‘Literature
BPS’ model based on equal weighting of 27 experimentally
verified BPSs from the literature (15–19,32–36). The BPS
profile models identified variable numbers of introns with
above-threshold matches ranging from 36 to 63%.
However, all BPS models identified a peak in the
expected BPS region. After subtracting the average back-
ground for each model in the range from 189 to 90,
from 86 to 90% of remaining best matches localized to
this region (Figure 4). We also included a well-established
U2AF65 affinity model describing the PPT(37) (Figure 4).
The U2AF65 Affinity Model had above-threshold
matches in 88% of introns, although a direct comparison
to the BPS profile models is precluded due to the more
constrained location of the PPT relative to the 30-splice
site and the lower sequence complexity of this motif.
Our SF1 Affinity Model had an improved SNR (defined
in ‘Materials and Methods’ section) of 1.10 compared to
the Initial SF1 Binding Model (0.81) but this SNR is lower
than those of the YNCURAY (1.63), Pentamer BPS (1.56)
and Literature BPS (1.19) models. Given that not all
introns are expected to bind SF1, our SF1-based model
is not expected to perform as well as others in predicting
all types of BPSs. However, the low SNR also may reflect
the inability of the SF1 Affinity Model to fully represent
SF1 binding affinity preferences due to the relatively
limited number of sequences with affinity data used for
model construction.
Pearson correlation coefficients between model scores
and SF1 affinity data provide another way to compare
models. As expected, the correlation coefficient for the
SF1 Affinity Model (0.39) is highest (Figure 4), although
all BPS models have correlation coefficients of at least
0.29. The U2AF65 Affinity Model (0.14) serves as an
uncorrelated control. A comparison of scatter plots
SF1 Affinity Initial SF1 Binding YNCURAY Literature BPS Pentamer BPS U2AF65 Affinity
% of above-background best 
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Signal to Noise
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SF1 affinity
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Figure 4. Evaluation of BPS and PPT profile models. Sequence logos representing each BPS and PPT profile model [Weblogo (29)] are shown with
statistics for each model: ‘% of Introns with Above Threshold Matches’ is the percent of introns with any profile match above threshold (‘Materials
and Methods’ section) in the entire intronic region from 199 to+1; ‘% of Above-Background Best Matches in Expected Region’ was determined by
first calculating an average background level of best matches at each position in the range from 189 to 90 from the 30-splice site, subtracting this
background value from number of best matches at each position, and comparing the number of these residual best matches in the expected BPS
region (BP A in 45 to 16) or PPT region (50-PPT start of match in the region from 30 to 11) to the number of expected background matches
in the expected region (‘Materials and Methods’ section); ‘Signal-to-Noise Ratio’ is the improvement over random based on the residual number of
best matches in the expected region relative to the background estimate; ‘Correlation with SF1 Affinity’ is the Pearson correlation coefficient between
profile model bit scores and SF1 affinities for the 46 sequences assayed.
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between the initial and final models (Figure 3G and H)
shows the relatively weak correlations and slight improve-
ment in the final SF1 Affinity Model. Of note, substituting
the register-shifted BPSs described above for the originally
selected BPSs results in higher correlation coefficients for
both the Initial SF1 Model (0.38) and SF1 Affinity Model
(0.47) (data not shown).
As a further test of model quality, we evaluated how
well the models predict a set of independently validated
BPSs in 50 introns from 20 human housekeeping genes
initially evaluated by Gao et al. (9). Each BPS was scored
using our models and the fraction correctly predicted was
calculated. No model showed high agreement
(Supplementary Table S5), but our SF1 Affinity Model
performed best (0.36) in the expected BPS region and in
the Gao et al. BPS range, suggesting that model refine-
ment using SF1 binding data enhances identification of
BPSs, whether or not they depend on SF1 for splicing.
While it is interesting that all BPS models exhibit some
correlation with SF1 binding affinities, even those derived
purely from sequence preferences, the generally weak per-
formance of the SF1 Affinity Model suggests that other
criteria are needed to enhance BPS predictions, support-
ing the view that the BPS itself is only one of several
factors that specify the location of the branch site (25).
Across the BPS models, C at position 3, U at position 4
and A at position 6 have the highest information content
(Figure 4). The sequence preferences of the Initial SF1
Binding Model are close to the yeast UACUAAC
sequence, but with more degeneracy. This in part may
be due to the limited and biased sequence data used to
construct the model. Nevertheless, it is interesting that the
preferences of the SF1 Affinity Model gravitate towards
the mammalian YNCURAY consensus, as all but the first
two positions of the SF1 Affinity Model consensus
sequence appear more degenerate than the YNCURAY
consensus, suggesting that a subset of SF1 binding sites
may function as BPSs, especially when localized to the
expected BPS region.
Identification of introns with potential SF1 binding sites
SF1 may not be a constitutive splicing factor but may act
at specific introns or participate in regulated or alternative
splicing (24). No SF1-dependent introns have yet been
identified nor have objective criteria been developed to
identify candidate introns. Our SF1 Affinity Model may
provide a tool for this purpose, particularly in conjunction
with the U2AF65 Affinity Model and spacing parameters
for the BPS and PPT that might approximate the coopera-
tive interaction of SF1 and U2AF65 when bound to RNA.
Combining BPS and PPT sequence-based models with
location criteria has been found to enhance BPS identifi-
cation (25). To test whether our affinity-weighted models
could help identify candidate SF1-dependent introns, we
searched our 148 643 intron data set to identify 10 introns
with high-BPS and high-PPT scores and with BPS
matches that have previously been experimentally
validated as functional BPSs (high BPS–high PPT, most
likely to bind SF1), 10 with low-BPS and high-PPT scores
(low BPS–high PPT, less likely to bind SF1), and 5 with
low BPS and low PPT scores (low BPS–low PPT, least
likely to bind SF1) (see ‘Materials and Methods’ section
for detailed selection parameters and Supplementary
Table S3 for list of introns) (Figure 5A). The distribution
of scores for all SF1 Affinity Model best matches scoring
above threshold in the expected BPS region is shown as
the histogram inset in Figure 5A. For high- and low-BPS
matches, respectively, we selected intronic regions with
SF1 Affinity Model scores in the top 12th percentile and
bottom 1st percentile of scores for all best-matches scoring
above threshold in the expected BPS region.
To evaluate SF1 binding in a relatively native sequence
context, we measured activities of Tat-fused SF1 on HIV
LTR reporters containing 100 nt upstream of each
30-splice site. Of the 10 intronic regions with high-BPS
and high-PPT scores (‘Materials and Methods’ section),
7 were bound by SF1 (compare to the mutant PPT
negative control; Figure 5A) whereas only one each of
the low BPS–low PPT and low BPS–high PPT sets
showed activity above that seen with the negative
control. The correlation between BPS scores and fold
activation in this data set (Figure 5B) produced a
Pearson correlation coefficient of 0.73, and there were
no obvious sequence similarities among the highly active
sequences. Binding of Tat-fused U2AF65 showed similar
activities across all reporters (data not shown), consistent
with the need for cooperative SF1/U2AF binding to
activate in these assays (3). Thus, SF1 and U2AF65
affinity parameters appear to provide useful tools to
identify candidate SF1-binding introns.
DISCUSSION
We constructed an SF1 affinity-weighted BPS profile
model using an iterative computational and experimental
approach and have used it as a tool to experimentally
identify candidate SF1-binding introns. The model
identifies possible SF1 binding sites located in the
expected BPS region with a frequency similar to that of
other BPS models that are based solely on sequence
information. Although none of the models perform
particularly well, the SF1 Affinity Model is able to
predict BPSs with higher accuracy than the other
models, based on a comparison using an independent set
of validated BPSs, suggesting that the requirements for
SF1 binding may be dictated by factors other than nucleo-
tide sequence. This is further highlighted by the low SNRs
exhibited by all models, which reflect in part the high de-
generacy of the sequence motifs and is consistent with the
suggestion that the BPS is one of just several features
needed to specify the branch site (25). However, when
the SF1 Affinity Model is combined with a U2AF65
Affinity Model and spacing of the sites is taken into
account to approximate the cooperative protein–protein
interaction on the RNA (‘Materials and Methods’
section), it is possible to successfully identify
SF1-binding introns. This approach is related to one in
which the BPS and PPT were scored based on sequence
preferences, without affinity data, and spaced only within
6 nt of each other (25). That study evaluated a smaller set
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Figure 5. SF1 binding to intronic region reporters using the Tat-hybrid assay. (A) Twenty-five 100-nt intronic regions were chosen from the intron
database based on SF1 Affinity Model criteria and were tested for binding using LTR FFL reporters in Tat-hybrid assays. HUGO gene names are
shown. High BPS–high PPT, low BPS–low PPT and low BPS–high PPT describe the intron selection criteria detailed in ‘Materials and Methods’
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of activation. The histogram in the inset shows the SF1 Affinity Model score distribution for high scoring matches in the expected region. (B)
Correlation between bit score calculated using the SF1 Affinity Model and measured SF1 affinities as in Figure 3H.
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of introns and achieved some statistical success, but
predicted BPSs were not examined experimentally and
the involvement of SF1 was not explicitly considered a
factor.
The SF1 Affinity Model identified sequences scoring
above a threshold in 55% of introns. Within the
expected BPS region, we found 87.9% of best matches
above threshold, after subtracting average background.
These estimates are consistent with previous suggestions
that not all human introns require SF1 for splicing (22,24).
Most high-scoring sequences outside the expected region
are likely to be false positives (26), but some branch points
have been found far upstream (35,48,49) and our model
correctly predicts the BPS as the highest scoring site in
three of four introns with known distant BPSs (human
PTB intron 10, rat -actinin intron 18, and rat
-tropomyosin intron 1; data not shown).
Our model is limited by several factors: the profile
model treats each position of the BPS independently and
thus cannot capture pairwise or higher order correlations
between nucleotides, such as base stacking preferences for
SF1 recognition (21). The SF1 affinity data used reflect a
cooperative interaction with U2AF65 and not the SF1–
BPS interaction alone, although it more faithfully repre-
sents the in vivo context. The model was constructed with
a relatively small sequence set biased toward the
tight-binding UACUAAC sequence. Some sequences
that bind SF1 have been incorporated into the model
but may not function as BPSs, such as AUAACCA and
GUCUUGA. Such sequences may represent binding sites
for other proposed SF1 functions, such as transcriptional
repression or nuclear mRNA retention (22,50), and it is
interesting that neither AUAACCA nor GUCUUGA
show a preferential distribution in the expected BPS
region (data not shown). Despite the lack of a BP A,
these sequences could still function as BPSs, especially if
located near a PPT. For example, a C located 28 nt
upstream of the 30-splice site is used as the branch point
in intron A of human growth hormone, and a U located
23 nts upstream of the 30-splice site is the branch point in
intron 4 of calcitonin/CGRP-I (33,34). Alternatively,
low-scoring sequences apparently bound by SF1 in our
reporter experiments (Figure 3) might actually reflect
binding to higher scoring sequences shifted in register by
one or more nucleotides, as highlighted by increased cor-
relation coefficients calculated using high-scoring shifted
sequences. Nevertheless, it is difficult to assess which cases
may reflect a register shift, but the number is expected to
be small and therefore not substantially change the SF1
Affinity Model.
Of the ten 100-nt intronic regions containing sequence
profile matches with high BPS and PPT scores tested using
the Tat-hybrid intronic context assay, three bound SF1
poorly (Figure 5). Despite their predicted high BPS
scores, two of these intronic regions, RNF41 and DOK5,
have predicted BPSs (Supplementary Table S3) that also
were bound poorly by SF1 in the context of the strong
adenovirus PPT (Figure 5). The third, TPK1, has a BPS
that was comparable to UACUAAC when assayed with
the adenovirus PPT, suggesting that binding in its native
context may be affected by the flanking RNA sequence or
structure or by the binding of other proteins.
Furthermore, other regions of the intron or surrounding
exons, not included in the reporters, may influence SF1
complex formation. Despite these limitations, our model
accurately identified introns bound by SF1 in the majority
of cases.
The sequences bound by SF1 are largely representative
of both the mammalian consensus BPS, YNCURAY (20),
as well as the recently published human consensus BPS,
YUNAY (9), suggesting that many of these sites function
as BPSs. Other sequences that conform to the consensus
but bind SF1 poorly may function as BPSs through an
SF1-independent mechanism or may require additional
factors to stabilize the SF1–BPS interaction not recruited
in the Tat-hybrid assay. Indeed, it has been proposed that
the U2 snRNP-BPS interaction may be mediated predom-
inantly by the SF3a and SF3b integral U2 snRNP
proteins, using sequences surrounding the BPS (51,52).
The p14 subunit of SF3b has been shown to crosslink to
the BP A of pre-mRNA, and the SF3b155 subunit of
SF3b interacts directly with U2AF65 (53). RNAi
knockdown of SF3a also causes a splicing defect in
several genes (24). It will be interesting to distinguish
which introns splice in SF1-dependent and -independent
modes and to compare their underlying splicing mechan-
isms and possible roles in regulating splicing.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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